The Chiefs will miss not only Leo Chenal’s versatility, but also his clutch plays. He is yet another valuable member of their 2022 NFL class who has moved on.

The Las Vegas Raiders learned that hard lesson Tuesday night when the Baltimore Ravens backed out of a blockbuster trade for star edge rusher Maxx Crosby. A person with knowledge of Baltimore’s ...

Exclusive: Mercedes chief leading swoop for same shares that former Red Bull principal is eyeing for return to F1 after sacking last year ...

Clare’s Irish Festival officially starts today, sponsored by MyMichigan Health. Here’s what’s going on throughout the ...

Miami Heat's Bam Adebayo exceeded Kobe Bryant's historic 81-point performance by scoring 83 against the Wizards.

CANOPY reports twelve strategies for creating a sustainable, future-proof office by 2026, focusing on effective design, ...

The Toronto Maple Leafs haven't replaced Brendan Shanahan with anyone as team president. Hockey Hall of Fame defenseman Chris ...

The Cheltenham Festival is now underway with favourite Lossiemouth winning the first big race yesterday, the Unibet Champion ...

A three-day training programme on Establishment of Agri-Tech Start-ups: Procedures and Challenges began on March 10 at the College of Agriculture under Rajmata Vijayaraje Scindia Krishi ...

NICE's AI ARR surged 66% to $328M, with cloud net revenue retention at 109%, supporting recurring growth and upsell opportunities. Read why NICE stock is a Buy.

A Bloomberg analysis suggests the nuclear push comes too late to stop China’s nuclear capacity from overtaking the U.S. fleet at the start of the next decade.

As Congress mulls whether to follow President Donald Trump’s orders for a most-favored-nation drug-pricing policy, biotech firm executives are starting to speak out against the measure.